Buchumschlag

Methotrexate-loaded liposomal formulation enables 6-week sustained intraocular therapeutic drug release in a porcine model

Methotrexate (MTX) inhibits cell proliferation, which underlies ocular diseases, including intraocular lymphoma and proliferative vitreoretinopathy. However, MTX normally requires bi-weekly intravitreal injections due to a short half-life, causing rapid clearance below therapeutic thresholds within...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hammer, Maximilian (VerfasserIn) , Skrzypczyk, Lea (VerfasserIn) , Wohlfart, Sabrina (VerfasserIn) , Ackermann, Bryan Calder (VerfasserIn) , Geisweid, Ludwig (VerfasserIn) , Pohl, Simon William (VerfasserIn) , Karaivanova, Margarita (VerfasserIn) , Herth, Jonathan (VerfasserIn) , Augustin, Victor A. (VerfasserIn) , Studier-Fischer, Alexander (VerfasserIn) , Sackmann, Tina (VerfasserIn) , Kaulen, Leon D. (VerfasserIn) , Steyer, Anna (VerfasserIn) , Mier, Walter (VerfasserIn) , Steel, David H. W. (VerfasserIn) , Xue, Kanmin (VerfasserIn) , Auffarth, Gerd U. (VerfasserIn) , Uhl, Philipp (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2025
In: Advanced healthcare materials
Year: 2025, Pages: 1-12
ISSN:2192-2659
DOI:10.1002/adhm.202503230
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1002/adhm.202503230
Verlag, kostenfrei, Volltext: http://onlinelibrary.wiley.com/doi/abs/10.1002/adhm.202503230
Volltext
Verfasserangaben:Maximilian Hammer, Lea Skrzypczyk, Sabrina Wohlfart, Bryan Calder Ackermann, Ludwig Geisweid, Simon William Pohl, Margarita Karaivanova, Jonathan Herth, Victor Aristide Augustin, Alexander Studier-Fischer, Tina Sackmann, Leon Kaulen, Anna Steyer, Walter Mier, David H Steel, Kanmin Xue, Gerd Uwe Auffarth, and Philipp Uhl
Beschreibung
Zusammenfassung:Methotrexate (MTX) inhibits cell proliferation, which underlies ocular diseases, including intraocular lymphoma and proliferative vitreoretinopathy. However, MTX normally requires bi-weekly intravitreal injections due to a short half-life, causing rapid clearance below therapeutic thresholds within 72h. To overcome these limitations, sustained-release carriers, including poly(lactic-co-glycolic) acid-based implants, were investigated in vitro previously. These systems offer prolonged drug delivery but require relatively large-gauge surgical implantation, which increases the risk of surgical complications and limits their practical use. In this study, MTX-loaded liposomes that can be administered via a 30-gauge cannula are developed, obviating the need for more invasive surgical implantation. This phospholipid-based liposomal formulation succeeded in enabling sustained methotrexate release at therapeutic levels for over six weeks following a single intravitreal injection, demonstrated in vivo in a large animal pig model. High biocompatibility of this novel liposomal formulation is confirmed through longitudinal retinal structure (optical coherence tomography) and function (electroretinography) assessments. This liposomal formulation of MTX provides a clinically and surgically optimized drug delivery system that allows improved management of intraocular lymphoma and proliferative vitreoretinopathy in the future.
Beschreibung:Erstmals veröffentlicht: 25. September 2025
Gesehen am 16.10.2025
Beschreibung:Online Resource
ISSN:2192-2659
DOI:10.1002/adhm.202503230

Ähnliche Einträge